The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
Open accessAbstract
Background: Desmoid tumors (deep fibromatoses) are clonal connective tissue malignancies that do not metastasize, but have a significant risk of local recurrence, and are associated with morbidity and occasionally mortality. Responses of desmoid patients to sorafenib on an expanded access program led us to review our experience. Methods: After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib. Sorafenib was administered at 400 mg oral daily and adjusted for toxicity. Results: Sorafenib was the first-line therapy in 11/26 patients and the remaining 15/26 had received a median of 2 prior lines of therapy. Twenty-three of 26 patients had shown evidence of progressive disease by imaging, whereas 3 patients had achieved maximum benefit or toxicity with chemotherapy. Sixteen of 22 (∼70%) patients reported significant improvement of symptoms. At a median of 6 months (2–29) of treatment, the best response evaluation criteria in solid tumors (RECIST) 1.1 response included 6/24 (25%) patients with partial response (PR), 17/24 (70%) with stable disease, and 1 with progression and death. Twelve of 13 (92%) patients evaluated by MRI had > 30% decrease in T2 signal intensity, an indirect metric for increased fibrosis and loss of cellularity. Eighty percent of patients with radiological benefit had extra-abdominal desmoids. Discussion: Sorafenib is active against desmoid tumors. A prospective, randomized clinical trial of sorafenib against other active agents is warranted. Loss of MRI T2 signal may be a useful surrogate for defining responses, but requires validation by examination of tumor pathology. Clin Cancer Res; 17(12); 4082–90. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K. K., & Mertens, F. (2002) · Medical Entomology and Zoology · Cited by 2,073
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Ballo, M. T., Zagars, G. K., Pollack, A., Pisters, P. W. T., & Pollock, R. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.158 · Cited by 501
Lewis, J. J., Boland, P. J., Leung, D. H. Y., Woodruff, J. M., & Brennan, M. F. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00014 · Cited by 327
Alman, B. A., Li, C., Pajerski, M. E., Díaz‐Cano, S. J., & Wolfe, H. J. (1997) · Europe PMC (PubMed Central) · Cited by 322
Heinrich, M. C., McArthur, G. A., Demetri, G. D., Joensuu, H., Bono, P., Herrmann, R., Hirte, H., Cresta, S., Koslin, D. B., Corless, C. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0717 · Cited by 318
Stacchiotti, S., Collini, P., Messina, A., Morosi, C., Barisella, M., Bertulli, R., Piovesan, C., Dileo, P., Torri, V., Gronchi, A., et al. (2009) · Radiology · doi:10.1148/radiol.2512081403 · Cited by 233
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
de Camargo, V. P., Keohan, M. L., D'Adamo, D. R., Antonescu, C. R., Brennan, M. F., Singer, S., Ahn, L. S., & Maki, R. G. (2010) · Cancer · doi:10.1002/cncr.25089 · Cited by 218
Self-citationHeinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
Severe Gardner syndrome in families with mutations restricted to a specific region of the APC gene.
Davies, D. E., Armstrong, J. G., Thakker, N., Horner, K., Guy, S. P., Clancy, T., Sloan, P., Blair, V., Dodd, C., & Warnes, T. W. (1995) · Europe PMC (PubMed Central) · Cited by 168
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu254 · Cited by 656
Alman, B., Attia, S., Baumgarten, C., Benson, C., Blay, J.-Y., Bonvalot, S., Breuing, J., Cardona, K., Casali, P. G., van Coevorden, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.013 · Cited by 506
Self-citationAdvances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Self-citationKasper, B., Baumgarten, C., Garcia, J., Bonvalot, S., Haas, R., Haller, F., Hohenberger, P., Penel, N., Messiou, C., van der Graaf, W. T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx323 · Cited by 422
Metadata
- Authors
- Gounder, M. M., Lefkowitz, R. A., Keohan, M. L., D'Adamo, D. R., Hameed, M., Antonescu, C. R., Singer, S., Stout, K., Ahn, L., & Maki, R. G.
- Venue
- Clinical Cancer Research
- Published
- 2011-06-15
- Volume
- 17
- Issue
- 12
- Pages
- 4082-4090
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2152015156
- Cited by
- 255
- References
- 13
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3322
- The paper
- Gounder, M. M., Lefkowitz, R. A., Keohan, M. L., D'Adamo, D. R., Hameed, M., Antonescu, C. R., Singer, S., Stout, K., Ahn, L., & Maki, R. G. (2011). Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.